Published on
Dec 20, 2024
A 'pivotal moment': Ionis enters next phase of commercial evolution with Tryngolza's FDA approval
With an FDA approval for Tryngolza (olezarsen) to treat the rare genetic disorder familial chylomicronemia syndrome (FCS), Ionis Pharmaceuticals enters a new era. While Ionis has gained several FDA nods in its 35 years in existence, Tryngolza will be the …
Source:
Fierce Pharma
-
Neutral
